Diabetes and baseline glucose are associated with inflammation, left ventricular function and short- and long-term outcome in acute coronary syndromes: role of the novel biomarker Cyr 61.
Patric WinzapAllan J DaviesRoland KlingenbergSlayman ObeidMarco RoffiFrançois MachLorenz RäberStephan WindeckerChristian TemplinFabian NietlispachDavid NanchenBaris GencerOlivier MullerChristian M MatterArnold von EckardsteinThomas F LüscherPublished in: Cardiovascular diabetology (2019)
In this large, prospective, independently adjudicated cohort of in all comers ACS patients undergoing PCI, both a history of diabetes and elevated entry glucose was associated with inflammation and increased risk of MACE both at short and long-term. The mediators might involve increased sympathetic activation, inflammation and ischemia as reflected by elevated Cyr61 levels leading to larger levels of troponin and lower LVEF. Trial registration Clinical Trial Registration Number: NCT01000701. Registered October 23, 2009.
Keyphrases
- acute coronary syndrome
- oxidative stress
- clinical trial
- type diabetes
- patients undergoing
- left ventricular
- cardiovascular disease
- percutaneous coronary intervention
- antiplatelet therapy
- acute myocardial infarction
- glycemic control
- blood glucose
- phase ii
- phase iii
- coronary artery disease
- randomized controlled trial
- atrial fibrillation
- double blind
- hypertrophic cardiomyopathy
- aortic stenosis
- weight loss